Knowns and unknowns in the care of pediatric familial hypercholesterolemia

Andrew C. Martin; Samuel S. Gidding; Albert Wiegman; Gerald F. Watts

doi:https://doi.org/10.1194/jlr.S074039

Knowns and unknowns in the care of pediatric familial hypercholesterolemia

Andrew C. Martin, Samuel S. Gidding, Albert Wiegman, Gerald F. Watts

Research output: Contribution to journal › Article › Academic › peer-review

35 Citations (Scopus)

Abstract

Familial hypercholesterolemia (FH) is a common genetic disorder that causes elevated LDL cholesterol levels from birth. Untreated FH accelerates atherosclerosis and predisposes individuals to premature coronary artery disease (CAD) in adulthood. Mendelian randomization studies have demonstrated that LDL cholesterol has both a causal and cumulative effect on the risk of CAD. This supports clinical recommendations that children with FH commence pharmacological treatment from the age of 8 to 10 years, to reduce the burden of hypercholesterolemia. Worldwide, the majority of children with FH remain undiagnosed. Recent evidence suggests that the frequency of FH is at least 1 in 250 and this constitutes a public health issue. We review and identify the knowns and unknowns concerning the detection and management of pediatric FH that impact on the developing model of care for this condition.- Martin, A. C., S. S. Gidding, A. Wiegman, and G. F. Watts. Knowns and unknowns in the care of pediatric familial hypercholesterolemia

Original language	English
Pages (from-to)	1765-1776
Journal	Journal of Lipid Research
Volume	58
Issue number	9
DOIs	https://doi.org/10.1194/jlr.S074039
Publication status	Published - 2017

Access to Document

https://doi.org/10.1194/jlr.S074039

Cite this

@article{4223f558002e4a0bac37b2277c6f407c,

title = "Knowns and unknowns in the care of pediatric familial hypercholesterolemia",

abstract = "Familial hypercholesterolemia (FH) is a common genetic disorder that causes elevated LDL cholesterol levels from birth. Untreated FH accelerates atherosclerosis and predisposes individuals to premature coronary artery disease (CAD) in adulthood. Mendelian randomization studies have demonstrated that LDL cholesterol has both a causal and cumulative effect on the risk of CAD. This supports clinical recommendations that children with FH commence pharmacological treatment from the age of 8 to 10 years, to reduce the burden of hypercholesterolemia. Worldwide, the majority of children with FH remain undiagnosed. Recent evidence suggests that the frequency of FH is at least 1 in 250 and this constitutes a public health issue. We review and identify the knowns and unknowns concerning the detection and management of pediatric FH that impact on the developing model of care for this condition.- Martin, A. C., S. S. Gidding, A. Wiegman, and G. F. Watts. Knowns and unknowns in the care of pediatric familial hypercholesterolemia",

author = "Martin, {Andrew C.} and Gidding, {Samuel S.} and Albert Wiegman and Watts, {Gerald F.}",

year = "2017",

doi = "https://doi.org/10.1194/jlr.S074039",

language = "English",

volume = "58",

pages = "1765--1776",

journal = "Journal of Lipid Research",

issn = "0022-2275",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "9",

}

TY - JOUR

T1 - Knowns and unknowns in the care of pediatric familial hypercholesterolemia

AU - Martin, Andrew C.

AU - Gidding, Samuel S.

AU - Wiegman, Albert

AU - Watts, Gerald F.

PY - 2017

Y1 - 2017

N2 - Familial hypercholesterolemia (FH) is a common genetic disorder that causes elevated LDL cholesterol levels from birth. Untreated FH accelerates atherosclerosis and predisposes individuals to premature coronary artery disease (CAD) in adulthood. Mendelian randomization studies have demonstrated that LDL cholesterol has both a causal and cumulative effect on the risk of CAD. This supports clinical recommendations that children with FH commence pharmacological treatment from the age of 8 to 10 years, to reduce the burden of hypercholesterolemia. Worldwide, the majority of children with FH remain undiagnosed. Recent evidence suggests that the frequency of FH is at least 1 in 250 and this constitutes a public health issue. We review and identify the knowns and unknowns concerning the detection and management of pediatric FH that impact on the developing model of care for this condition.- Martin, A. C., S. S. Gidding, A. Wiegman, and G. F. Watts. Knowns and unknowns in the care of pediatric familial hypercholesterolemia

AB - Familial hypercholesterolemia (FH) is a common genetic disorder that causes elevated LDL cholesterol levels from birth. Untreated FH accelerates atherosclerosis and predisposes individuals to premature coronary artery disease (CAD) in adulthood. Mendelian randomization studies have demonstrated that LDL cholesterol has both a causal and cumulative effect on the risk of CAD. This supports clinical recommendations that children with FH commence pharmacological treatment from the age of 8 to 10 years, to reduce the burden of hypercholesterolemia. Worldwide, the majority of children with FH remain undiagnosed. Recent evidence suggests that the frequency of FH is at least 1 in 250 and this constitutes a public health issue. We review and identify the knowns and unknowns concerning the detection and management of pediatric FH that impact on the developing model of care for this condition.- Martin, A. C., S. S. Gidding, A. Wiegman, and G. F. Watts. Knowns and unknowns in the care of pediatric familial hypercholesterolemia

U2 - https://doi.org/10.1194/jlr.S074039

DO - https://doi.org/10.1194/jlr.S074039

M3 - Article

C2 - 28701353

SN - 0022-2275

VL - 58

SP - 1765

EP - 1776

JO - Journal of Lipid Research

JF - Journal of Lipid Research

IS - 9

ER -